≥ 140mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorbreastcancerq1y≥6.5%q2y≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsmultidoseinitial series,then 1 doseat 2-6monthsq1-2ymammogrambased on lifeexpectancy /health statuscervicalcancerdementiaaromataseinhibitors≤q2y3%q5ydepressionq1ymammogram≥ 200mg/dLtobaccouseinsufficientevidenceforscreeningcardiovasculardiseasewomenage 55-64 y.o.hormonetherapypneumococcal≥20%aspirinanxiety40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≥ 126mg/dL65y.o.tamoxifenraloxifeneHIVcommunity-dwelling,postmenopausalwomenGailmodel40-70 y.o.,ASCVD ≥10%, lowbleeding risk40-59 y.o.,ASCVD ≥10%, lowbleeding risk≥ 100mg/dL52y.o.herpeszoster40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥5.7%Timedup andgo test40y.o.< 60y.o.colorectalcancerHepatitisBq3yq15ydyslipidemiadiabetesoverweight/ obesity60y.o.PREVENTequationlungcancer2 doses,2-6monthsapart50y.o.Tyrer-CuzickmodelHepatitisCovariancancer1 dose; 2doses (2-6monthsapart) ifimmunocomp75y.o.hypertensionFractureRiskAssessmentToolstatin≥ 140mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorbreastcancerq1y≥6.5%q2y≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsmultidoseinitial series,then 1 doseat 2-6monthsq1-2ymammogrambased on lifeexpectancy /health statuscervicalcancerdementiaaromataseinhibitors≤q2y3%q5ydepressionq1ymammogram≥ 200mg/dLtobaccouseinsufficientevidenceforscreeningcardiovasculardiseasewomenage 55-64 y.o.hormonetherapypneumococcal≥20%aspirinanxiety40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≥ 126mg/dL65y.o.tamoxifenraloxifeneHIVcommunity-dwelling,postmenopausalwomenGailmodel40-70 y.o.,ASCVD ≥10%, lowbleeding risk40-59 y.o.,ASCVD ≥10%, lowbleeding risk≥ 100mg/dL52y.o.herpeszoster40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥5.7%Timedup andgo test40y.o.< 60y.o.colorectalcancerHepatitisBq3yq15ydyslipidemiadiabetesoverweight/ obesity60y.o.PREVENTequationlungcancer2 doses,2-6monthsapart50y.o.Tyrer-CuzickmodelHepatitisCovariancancer1 dose; 2doses (2-6monthsapart) ifimmunocomp75y.o.hypertensionFractureRiskAssessmentToolstatin

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. ≥ 140 mg/dL
  2. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  3. breast cancer
  4. q1y
  5. ≥ 6.5%
  6. q2y
  7. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  8. multidose initial series, then 1 dose at 2-6 months
  9. q1-2y mammogram based on life expectancy / health status
  10. cervical cancer
  11. dementia
  12. aromatase inhibitors
  13. ≤ q2y
  14. 3%
  15. q5y
  16. depression
  17. q1y mammogram
  18. ≥ 200 mg/dL
  19. tobacco use
  20. insufficient evidence for screening
  21. cardiovascular disease
  22. women age 55-64 y.o.
  23. hormone therapy
  24. pneumococcal
  25. ≥ 20%
  26. aspirin
  27. anxiety
  28. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  29. ≥ 126 mg/dL
  30. 65 y.o.
  31. tamoxifen
  32. raloxifene
  33. HIV
  34. community-dwelling, postmenopausal women
  35. Gail model
  36. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  37. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  38. ≥ 100 mg/dL
  39. 52 y.o.
  40. herpes zoster
  41. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  42. ≥ 5.7%
  43. Timed up and go test
  44. 40 y.o.
  45. < 60 y.o.
  46. colorectal cancer
  47. Hepatitis B
  48. q3y
  49. q15y
  50. dyslipidemia
  51. diabetes
  52. overweight / obesity
  53. 60 y.o.
  54. PREVENT equation
  55. lung cancer
  56. 2 doses, 2-6 months apart
  57. 50 y.o.
  58. Tyrer-Cuzick model
  59. Hepatitis C
  60. ovarian cancer
  61. 1 dose; 2 doses (2-6 months apart) if immunocomp
  62. 75 y.o.
  63. hypertension
  64. Fracture Risk Assessment Tool
  65. statin